October Newsmakers

Bringing WISDOM to Breast Cancer Care (Time Magazine)
Features Shelley Hwang, MD

Black men particularly at risk to develop, die from prostate cancer (Charlotte Post)
Features Andrew Armstrong, MD, MSc

'Definitely missed': Fayetteville family enters Breast Cancer Awareness Month after loss of mother (WTVD-Ch. 11)
Features Angelo Moore, PhD, RN

NBNA Announces New Board of Directors and Nominations Committee 2021-2022 (Minority Nurse)
*Angelo Moore, PhD, RN, has been elected to the National Black Nurses Association Board of Directors

Racial disparities in cancer clinical trials: ‘An old problem with new implications’ (Healio)
Features Leah Zullig, PhD

Duke and UC scientists find a potential remedy for chronic pain from a 'junkyard of cancer drugs' (Fierce Biotech)
Features Ru-Rong Ji, PhD, Wolfgang Liedtke, MD, PhD

Watch & Listen

OncLive, in collaboration with the Duke Cancer Institute Hematologic Malignancies & Cellular Therapy Disease Group, hosted "Institutional Perspectives in Cancer: Leukemia/Lymphoma" on Tuesday, October 5, from 5:30 p.m. to 7 p.m.

Here are some clips from that event:

BTK Inhibitors, PI3K Inhibitors, and CAR T-Cell Therapy Shake Up Hematologic Malignancies Armamentarium
Features Harry Erba, MD, PhD

Expanding role of BTK inhibitors in MCL
Features Matthew McKinney, MD

Other

Identifying PIK3CA Mutations in HR+ HER2- MBC (OncLive ESMO wrap)
Sarah Sammons, MD

Frontline Treatment Approaches for HR+/HER2- MBC (OncLive ESMO wrap)
Sarah Sammons, MD

HR+ MBC: Prognostic Factors and Treatment Planning (OncLive ESMO wrap)
Sarah Sammons, MD

Frontline Treatment Approaches for HR+/HER2- MBC (OncLive ESMO wrap)
Sarah Sammons, MD

HR+/HER2- MBC: Updated OS Data From MONALEESA-2 (OncLive ESMO wrap)
Sarah Sammons, MD

HR+/HER2- MBC: CDK4/6 Inhibitors + ET as Frontline Therapy (OncLive ESMO wrap)
Sarah Sammons, MD

HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities
(OncLive ESMO wrap)
Sarah Sammons, MD

WATCH: Design of the OReO trial in ovarian cancer (OncLive)
Angeles Alvarez Secord, MD, MHSc

WATCH: Community Conversation on Ovarian Cancer (DCI Blog)
Features Alvarez Secord, MD, MHSc; Rafael Gonzalez, MD; Maggie (Powell) Frazier, MS, CGC

WATCH: What's Best for Breasts ? A Conversation with Duke Clinicians (DCI Blog)
Features Tomi Akinyemiju, PhD, MS; Jay Baker, MD; Colin Champ, MD; Gayle DiLalla, MD; Susan McDuff, MD; LaSonia Barnett, MA; Jennifer Plichta, MD, MD; Laura Rosenberger, MD; Kathy Trotter DNP, FAANP; Kelly Westbrook, MD; Jackie White, NP; Hannah Woriax, MD; Marguerite Rooney, MS3; Nadia Aguilera-Funez, BA.

WATCH Final Thoughts on New Developments and Emerging Agents (OncLive)
Features Harry P. Erba, MD, PhD

WATCH 5-Year Follow-up Data on CPX-351 for AML (OncLive)
Features Harry Erba, MD, PhD

WATCH: Evolving Treatment Approaches Pre- and Post-Transplant (OncLive)
Features Harry P. Erba, MD, PhD

Treatment Approaches for TP53-Mutated AML (OncLive)
Features Harry P. Erba, MD, PhD

WATCH: Dr. Ready on Selecting Between Frontline Atezolizumab and Durvalumab in ES-SCLC (OncLive)
Features Neal Ready, MD

Dr. Ready on the Role of Frontline Chemoimmunotherapy in Lung Cancer (OncLive)
Features Neal Ready, MD